The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.

导出 OA

翻译打印收藏纠错

作者： Richard,Copin ^[1] ; Alina,Baum ^[1] ; Elzbieta,Wloga ^[1] ; Kristen E,Pascal ^[1] ; Stephanie,Giordano ^[1] ; Benjamin O,Fulton ^[1] ; Anbo,Zhou ^[1] ; Nicole,Negron ^[1] ; Kathryn,Lanza ^[1] ; Newton,Chan ^[1] ; Angel,Coppola ^[1] ; Joyce,Chiu ^[1] ; Min,Ni ^[1] ; Yi,Wei ^[1] ; Gurinder S,Atwal ^[1] ; Annabel Romero,Hernandez ^[1] ; Kei,Saotome ^[1] ; Yi,Zhou ^[1] ; Matthew C,Franklin ^[1] ; Andrea T,Hooper ^[1] ; Shane,McCarthy ^[1] ; Sara,Hamon ^[1] ; Jennifer D,Hamilton ^[1] ; Hilary M,Staples ^[2] ; Kendra,Alfson ^[2] ; Ricardo,Carrion ^[2] ; Shazia,Ali ^[1] ; Thomas,Norton ^[1] ; Selin,Somersan-Karakaya ^[1] ; Sumathi,Sivapalasingam ^[1] ; Gary A,Herman ^[1] ; David M,Weinreich ^[1] ; Leah,Lipsich ^[1] ; Neil,Stahl ^[1] ; Andrew J,Murphy ^[1] ; George D,Yancopoulos ^[1] ; Christos A,Kyratsous ^[3]

作者单位： Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. ^[1] Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78245, USA. ^[2] Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. Electronic address: christos.kyratsous@regeneron.com. ^[3]

关键词 COVID-19 REGEN-COV SARS-CoV-2 escape monoclonal antibodies